← FDA DRUG APPROVALS

FDA ANDA · ANDA075848

OXAPROZIN

Sponsor: WATSON LABS

APPLICATION
ANDA075848
TYPE
ANDA
ORIGINAL APPROVAL
2001-02-09
LATEST ACTION
2026-01-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

OXAPROZINDiscontinued
OXAPROZIN 600MG · TABLET · ORAL

Approval history

2026-01-22Labeling · Supplement 7 · standardAP
2004-07-19Labeling · Supplement 4AP
2002-11-07Manufacturing (CMC) · Supplement 2AP
2002-06-07Manufacturing (CMC) · Supplement 1AP
2001-02-09OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →